Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation and Study of Diabetic Nephropathy with Atrasentan: what was learned about the treatment of diabetic kidney disease with canagliflozin and atrasentan?

In April 2019, two major Phase 3 randomized clinical trials were published that assessed primary renal outcomes in diabetic kidney disease (DKD) in type 2 diabetes mellitus (T2DM). The Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) tested an al...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Clin Kidney J
Hlavní autoři: Fernandez-Fernandez, Beatriz, Fernandez-Prado, Raul, Górriz, Jose Luis, Martinez-Castelao, Alberto, Navarro-González, Juan F, Porrini, Esteban, Soler, María José, Ortiz, Alberto
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2019
Témata:
Sglt2 Inhibitors
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6543971/
https://ncbi.nlm.nih.gov/pubmed/31198532
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ckj/sfz070
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky